1
![Aerie Pharmaceuticals]()
![Aerie Pharmaceuticals]()
![Aerie Pharmaceuticals]()
Aerie Pharmaceuticals
Leadership team
Casey C. Kopczynski (Founder)
Thomas J. van Haarlem (Founder)
Products/ Services
Biotechnology, Health Care, Medical, Pharmaceutical
Number of Employees
100 - 500
Headquarters
Bedminster, New Jersey, United States
Established
2005
Company Registration
SEC CIK number: 0001337553
Traded as
NASDAQ:AERI
Overview
Location
Summary
Aerie Pharmaceuticals, Inc. is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye.
History
Aerie Pharmaceuticals was founded in 2006 and is headquartered in Durham, North Carolina. The company’s strategy is to continue to progress late-stage glaucoma products, expand its pipeline of earlier-stage clinical candidates for glaucoma and create value for glaucoma patients, their families and healthcare providers.
Mission
To bring meaningful change to patients with glaucoma and other diseases of the eye through innovative science and passionate people.
Vision
To make a meaningful difference in the lives of those touched by eye disease through dedication and commitment to innovation.
Key Team
Casey C. Kopczynski (Founder)
Thomas J. van Haarlem (Founder)
Recognition and Awards
Aerie Pharmaceuticals has been awarded the 2019 Silver Edison Award in the Health & Wellness category for its novel medication, Rhopressa.
References
Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.
Leadership team
Casey C. Kopczynski (Founder)
Thomas J. van Haarlem (Founder)
Products/ Services
Biotechnology, Health Care, Medical, Pharmaceutical
Number of Employees
100 - 500
Headquarters
Bedminster, New Jersey, United States
Established
2005
Company Registration
SEC CIK number: 0001337553
Traded as
NASDAQ:AERI